Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment

D Bergqvist; Amiram Eldor; Ole Thorlacius‐Ussing; S. Combe; G.A. Gardiner; J. Toouli; J. F. Cade; S Boesby; D. Varon; Giorgio Bolis; Luigi Bonavina; P Pietri; Arild Horn; O Reiertsen; Johan N. Wiig; Lars Påhlman; Lars Norgren; Bernhard Ø. Palsson; Anders Törnqvist; Theo Wiggers; Renae Lyons; Robert D. Smink; Arthur A. Trowbridge; Chris Joyce; M O Koch; Charles Levenback; James V. Fiorica; J Mowler; D Green; David Bodensteiner; A. Cohen

doi:10.1046/j.1365-2168.1997.d01-3882.x

Why the study?

Does enoxaparin 40 mg once daily prevent deep vein thrombosis compared to unfractionated heparin in patients undergoing elective cancer surgery?

Key Points

To assess the efficacy and safety of once-daily enoxaparin compared with three-times-daily unfractionated heparin for preventing deep vein thrombosis in patients undergoing elective surgery for malignant disease.
Conducted a double-blind, randomized multicentre trial in patients undergoing elective cancer surgery.
Assigned patients to receive either low molecular weight heparin (enoxaparin, 40 mg once daily starting 2 hours preoperatively) or low-dose unfractionated heparin (three times daily).
Assessed postoperative deep vein thrombosis using bilateral venography.
The comparative efficacy of once-daily enoxaparin against thrice-daily unfractionated heparin was evaluated based on venographically confirmed deep vein thrombosis.
Safety outcomes and bleeding risks were monitored postoperatively between the low molecular weight heparin and unfractionated heparin arms.

Structured PICO

Does enoxaparin 40 mg once daily prevent deep vein thrombosis compared to unfractionated heparin in patients undergoing elective cancer surgery?

P

Population

Patients undergoing elective cancer surgery (surgery for malignant disease)

I

Intervention

Enoxaparin 40 mg once daily, beginning 2 h before surgery

C

Comparator

Unfractionated low-dose heparin three times daily

O

Outcome

Deep vein thrombosis (assessed by venography)hard clinical

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Supports once-daily enoxaparin for DVT prophylaxis in cancer surgery; extends RCT evidence for simplified LMWH dosing versus UFH.

Abstract

BackgroundSurgery for malignant disease carries a high risk of deep vein thrombosis. The aim of this study was to evaluate the prophylactic effect of a low molecular weight heparin, enoxaparin, 40 mg once daily, beginning 2 h before surgery, compared with that of unfractionated low-dose heparin three times daily.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bergqvist et al. (1997) studied this question.

synapsesocial.com/papers/6a7d31e9c66da78fab8b272c https://doi.org/10.1046/j.1365-2168.1997.d01-3882.x

View at Publisher

Ask AI

Bookmark

Share

Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading